Show simple item record

dc.contributor.authorGreenwood, Bonnie C.
dc.date2022-08-11T08:08:07.000
dc.date.accessioned2022-08-23T15:43:00Z
dc.date.available2022-08-23T15:43:00Z
dc.date.issued2018-09-27
dc.date.submitted2018-10-11
dc.identifier.doi10.13028/zne3-q393
dc.identifier.urihttp://hdl.handle.net/20.500.14038/26985
dc.description<p>Blog post to Commonwealth Medicine's website - <a href="https://commed.umassmed.edu/blog/2018/09/27/view-drug-pricing-blueprint" target="_blank">View blog post online</a></p>
dc.description.abstractDrug spend is predicted to experience the fastest annual growth between 2017-2026 compared to other health care goods and services.Contributing factors include increasing unit prices of branded and generic medications, growth of the specialty drug market, and greater numbers of people with access to prescription drug coverage. A recent analysis estimates total drug expenditures in 2016 to be $480 billion when accounting for gross profits of intermediaries in the distribution chain, such as wholesalers, pharmacy benefit managers (PBMs), and pharmacies. Certainly, the complexity of the drug distribution and reimbursement system and lack of pricing transparency can be viewed both as symptoms of and barriers to solving this issue.
dc.language.isoen_US
dc.rights© 2018 University of Massachusetts Medical School
dc.subjectdrug prices
dc.subjectHealth Economics
dc.subjectHealth Law and Policy
dc.subjectHealth Policy
dc.subjectHealth Services Administration
dc.subjectHealth Services Research
dc.subjectPharmacoeconomics and Pharmaceutical Economics
dc.titleA view of the drug pricing blueprint
dc.typeBlog Post
dc.identifier.legacyfulltexthttps://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=1211&amp;context=commed_pubs&amp;unstamped=1
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/commed_pubs/213
dc.identifier.contextkey13063783
refterms.dateFOA2022-08-23T15:43:00Z
html.description.abstract<p>Drug spend is predicted to experience the fastest annual growth between 2017-2026 compared to other health care goods and services.Contributing factors include increasing unit prices of branded and generic medications, growth of the specialty drug market, and greater numbers of people with access to prescription drug coverage. A recent analysis estimates total drug expenditures in 2016 to be $480 billion when accounting for gross profits of intermediaries in the distribution chain, such as wholesalers, pharmacy benefit managers (PBMs), and pharmacies. Certainly, the complexity of the drug distribution and reimbursement system and lack of pricing transparency can be viewed both as symptoms of and barriers to solving this issue.</p>
dc.identifier.submissionpathcommed_pubs/213
dc.contributor.departmentCommonwealth Medicine, Clinical Pharmacy Services


Files in this item

Thumbnail
Name:
a_view.pdf
Size:
121.2Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record